Lumos Diagnostics (ASX:LDX) share price climbs amid RAT mania

Lumos share price rises amid RAT test drama

| More on:
a group of doctors and medical staff in uniform high five in celebration in a hospital setting

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Lumos Diagnostics share price is rising today
  • COVID-19 rapid antigen tests are in focus this week
  • The company's CoviDX RAT test is waiting on TGA approval

The Lumos Diagnostics Holdings Ltd (ASX: LDX) share price is rising today as COVID-19 rapid antigen tests (RATS) hit the headlines.

At the time of writing, the company's share price is trading hands at 1.01, up 1.5%.

Let's take a look at what might be impacting the company's share price.

Awaiting TGA approval

The Lumos Diagnostics share price has been skyrocketing in recent weeks as demand for COVID-19 RAT tests increases globally.

Since Christmas Eve, the company's shares have gained 44%, rising from 70 cents to the current share price. Lumos Diagnostics achieved record revenue of $22.7 million in the 2021 financial year, up 188% from FY2020.

The company is one of a few in Australia — including Brisbane-based AnteoTech (ASX: ADO) — waiting on TGA approval for its diagnostic test despite lodging the application in September, ABC News reported.

Executive chairman Sam Lanyon told the publication.

We're working with the TGA on adding some additional clinical data to the application".

The company currently has manufacturing facilities for its rapid antigen tests in Florida and California in the United States, but not Australia.

In an investor presentation provided to the market in August, the company said it is hoping to launch its CoviDx rapid COVID-19 antigen test solution in the US, Canada and Australia in FY22 pending regulatory approvals.

This CoviDX RAT can return a result within 15 minutes of a viral swab.

The company approached Federal and State governments about local manufacture of the tests from mid-2020, but got nowhere with these discussions due to the preference for PCR tests, the ABC reported. Mr Laynson said:

For that reason, we set up our manufacturing capability out of Florida and California, which is there today, providing our range of tests into the US, European and Canadian markets at this point in time.

Lumos also has another flagship product, FebriDX, which can tell the difference between bacterial and viral infections. This product was launched in more than 100 pharmacies in the UK this week. FebriDX is also approved in Europe, Canada and Australia.

Share price snapshot

The Lumos Diagnostics share price has shed 19% in the past 52 weeks but is up 29% in the past month.

For comparison, the S&P/ASX 200 Index (ASX: XJO) has returned nearly 11% to investors in the past year.

The company commands a market capitalisation of roughly $152 million based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »